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Available online 7 July 2016To extend previous models of hexavalent chromium [Cr(VI)] reduction by gastric ﬂuid (GF), ex vivo experiments
were conducted to address data gaps and limitations identiﬁed with respect to (1) GF dilution in the model; (2)
reduction of Cr(VI) in fed human GF samples; (3) the number of Cr(VI) reduction pools present in human GF
under fed, fasted, and proton pump inhibitor (PPI)-use conditions; and (4) an appropriate form for the pH-de-
pendence of Cr(VI) reduction rate constants. Rates and capacities of Cr(VI) reduction were characterized in gas-
tric contents from fed and fasted volunteers, and from fasted pre-operative patients treatedwith PPIs. Reduction
capacitieswereﬁrst estimated over a 4-h reduction period. Once reduction capacitywas established, a dual-spike
approach was used in speciated isotope dilution mass spectrometry analyses to characterize the concentration-
dependence of the 2nd order reduction rate constants. These data, when combined with previously collected
data, were well described by a three-pool model (pool 1 = fast reaction with low capacity; pool 2 = slow reac-
tion with higher capacity; pool 3= very slow reaction with higher capacity) using pH-dependent rate constants
characterized by a piecewise, log-linear relationship. These data indicate that human gastric samples, like those
collected from rats and mice, contain multiple pools of reducing agents, and low concentrations of Cr(VI) (b0.7
mg/L) are reduced more rapidly than high concentrations. The data and revisedmodeling results herein provide
improved characterization of Cr(VI) gastric reduction kinetics, critical for Cr(VI) pharmacokinetic modeling and
human health risk assessment.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Hexavalent chromium
stomach reduction kinetics
human gastric ﬂuid
Speciated Isotope Dilution Mass Spectrometry
(SIDMS)1. Introduction
Drinkingwater consumption of high concentrations (5 to 180mg/L)
of hexavalent chromium [Cr(VI)] has been found to produce tumors in
the small intestines of mice following lifetime oral exposures (NTP,
2008). However, it has been recognized for several decades that Cr(VI)
can be detoxiﬁed via extracellular reduction to inert trivalent chromium
[Cr(III)] in the gastrointestinal lumen (De Flora et al., 1987; De Flora,.R. Kirman),
ogy.com (S.M. Hays),
com (R. Gerads), sdf@unige.it
in@duke.edu (S. Lin),
ies.com (M.A. Harris),
. This is an open access article under2000). Characterization of the rates and capacities for Cr(VI) reduction
by gastric ﬂuid (GF) prior to reaching critical target tissues in the
small intestine (i.e., intestinal mucosa cells) is important for informing
extrapolations of toxicity observed across species and for understanding
the potential cancer risk posed by environmental exposure to Cr(VI) in
the drinkingwater supply. The rate of Cr(VI) reduction can be described
by the following generalized equation:
RateofReduction mg=hrð Þ¼CCrVI x KRed x CREð ÞPool 1þ… KRed x CREð ÞPool N
 
ð1Þ
Where KRed is a second order rate constant for reduction (L2/mg-hr)
for a speciﬁc pool of reducing equivalents, CRE is the concentration of re-
ducing equivalents or reduction capacity (mg/L) for a speciﬁc pool ofthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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number of pools; and values for KRed and CRE differ between pools (i.e.,
reduction reactions can occur at different rates, with different capaci-
ties). The term reducing equivalent is used here for the sake of simplic-
ity to refer to a pool of three-electron donors needed to reduce Cr(VI) to
Cr(III). By collecting andmodeling time-course data collected for the re-
duction of Cr(VI) by GF, we can characterize the rates, capacities, and
pH-dependence of the reaction, which is then used in a physiologically
based pharmacokinetic model for chromium (Fig. 1).
The capacity of GF for Cr(VI) reduction (CRE) has been characterized
in human and animal studies. Based on an s-diphenylcarbazide (DPC)
colorimetric method, De Flora et al. (1987) reported time-dependent
changes in the capacity of GF to reduce Cr(VI) in 16 hospital patients
with duodenal ulcer and one healthy volunteer. Shortly after a meal,
peak reduction capacities were reported as a single pool ranging from
40 to 60mg/L,while reduction capacities betweenmealswere generally
below 10 mg/L. Conﬁrming the latter value, Kirman et al. (2013) esti-
mated a reduction capacity for a single pool of 7 mg/L in combined GF
samples from ten fasted, preoperative cardiac patients using a simple
(single, 2nd order reaction) reduction model. Analyzing the same data
as Kirman et al. (2013) with a more complex reduction model,
Schlosser and Sasso (2014) reported a slightly higher reduction capacity
for a single pool of approximately 10 mg/L in fasted human samples.
Overall, despite differences in analytical methods or modeling ap-
proaches, the capacity estimates for fasted samples from these studies
(De Flora et al., 1987; Kirman et al., 2013; Schlosser and Sasso, 2014)
are generally consistent. With respect to capacity in GF from laboratory
rodents, Proctor et al. (2012) reported that the reduction capacity for GF
samples from fed rats andmicewas approximately 16mg/L using a sim-
ple, single reduction pool model. Reanalysis of the same data by
Schlosser and Sasso (2014) using a multi-pool model, including fastFig. 1. Role of ex vivo reduction data (A) in developing a rand slow reduction reactions, yielded slightly higher reduction capaci-
ties. Speciﬁcally, reduction capacities in mouse GF of 2.9 and 31 mg/L
for the fast and slow pools, respectively, were reported, while values
of 4.1 and 18mg/Lwere reported for the fast and slow pools, respective-
ly, in rat GF.
The number of reducing agent pools present in GF (N in Eq. (1)) is an
important determinant of risk that can affect interspecies extrapolation
as well as high-to-low dose extrapolation. In our previous work charac-
terizing the reduction of Cr(VI) by human and rodent GF, we modeled
all data using a single-pool model (Proctor et al., 2012; Kirman et al.,
2013). Using a revised gastric model, Schlosser and Sasso (2014) relied
upon a single-pool model for humans, and a three-pool model for labo-
ratory rodents based upon available ex vivo reduction data, and in so
doing may have created an apparent species difference (three pools in
rodents vs. one pool in humans). However, the single pool used to
model the human data may reﬂect insufﬁcient information that was
previously available to allow for differentiation of more than one pool,
rather than a true species difference. Speciﬁcally, to address the pres-
ence of multiple reducing agent pools, GF samples need to be assessed
using a wide range of Cr(VI) spike concentrations. In our previous
study of human GF (Kirman et al., 2013), a limited number of human
fasted samples were used to characterize reduction across different
pH values using a fairly narrow range of Cr(VI) spike concentrations.
In rodent GF, pH is far less variable than in humans, and we were able
to characterize Cr(VI) reduction across a wide range of concentrations
(Proctor et al., 2012). Samples were spiked at a range of concentrations
representative of the high concentrations used in the rodent cancer bio-
assay (180 ppm) as well as much lower concentrations consistent with
the federal drinking water standard (0.1 ppm).
The reduction of Cr(VI) by human GF is pH dependent, with faster
rates of reduction occurring at low pH compared to those at high pHeduction model (B) and a PBPK model for Cr(VI) (C).
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pH-dependent behaviors have been reported for speciﬁc reducing
agents that likely serve as constituents of GF, including glutathione
(Wiegand et al., 1984) and ascorbate (Dixon et al., 1993). However,
the behavior of this pH dependence (i.e., the shape of the reduction con-
stant curve as a function of pH) is less clear. The nature of the pH-depen-
dence for the rate of Cr(VI) reduction serves as an important component
of the risk assessment, because it determines the rate of detoxiﬁcation
of Cr(VI) in the stomach between meals (low pH), during meals (shortFig. 2. pH Dependence of Cr(VI) Forms: (A) Showing speciﬁc forms of Cr as described by Eqs
participating in oxidation/reduction reactions, which is calculated as the sum of all forms of C
The general shape of the pH dependence for this model includes plateaus at observed at p
H2CrO4 = dihydrogen chromate; HCrO4- = hydrogen chromate; CrO42- = chromate; HCr2O7- =term increase in pH), as well as in potentially sensitive subpopulations
with elevated gastric pH levels (e.g., neonates and users of proton
pump inhibitors or PPIs). Kirman et al. (2013) assumed an empirical,
log-linear relationship between pH and reduction rate constant (i.e.,
Kred from Eq. (1) is expressed as a log-linear function of pH) to help ex-
plain the faster reduction rates observed for Cr(VI) at low pH compared
to those observed at high pH. Subsequently, Schlosser and Sasso (2014)
developed amore complex reductionmodel to improve the ﬁt of model
predictions to the available data. This reduction model included a. (2)-(5) (see text); (B) pH dependence of the predominance model. The fraction of CrVI
rVI, with CrO4-2 weighted by a factor of 0.025, as deﬁned by Schlosser and Sasso (2014).
H values above and below an inﬂection point that is determined by the value of pK11.
dichromate.
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consideration of the predominance of Cr(VI) forms present at a given
pH (Fig. 2A), with the predominance of the different forms of Cr(VI) de-
ﬁned by the following equations (Brito et al., 1997; Schlosser and Sasso,
2014):
CrO2−4 þ Hþ↔HCrO−4 ;K11 ¼
HCrO−4
 
CrO2−4
h i
Hþ
  ð2Þ
2HCrO−4 ↔Cr2O
2−
7 þH2O;K22 ¼
Cr2O
2−
7
h i
HCrO−4
 2 ð3Þ
HCrO−4 þHþ↔H2CrO4;K21 ¼
H2CrO4½ 
HCrO−4
 
Hþ
  ð4Þ
Cr2O
2−
7 þ Hþ↔HCr2O−7 ;K32 ¼
HCr2O
−
7
 
Cr2O
2−
7
h i
Hþ
  ð5Þ
Brito et al. (1997) published the following values to describe chromi-
um speciation equilibria: K11= 7.73x105 M-1 (pK11= 5.89), K22 = 132
M-1 (pK22 = 2.12), K21 = 13.2 M-1 (pK21 = 1.12), and K32 = 15.2 M-1
(pK32 = 1.28). The forms of Cr(VI) that predominate at low pH have
high redox potentials (e.g., H2CrO2. E0 = +1.33 V), while the form of
Cr(VI) that predominates at high pH has a low redox potential (CrO42-
E0 = -0.12 V), a pattern that is consistent with a higher rate of Cr(VI)
reduction at lower pH than at higher pH. Schlosser and Sasso (2014)
have proposed that the pH dependence of Cr(VI) reduction can be at-
tributed the predominance of the form of Cr(VI) present at a given pH
(i.e., the CCrVI term in Eq. (1) is replaced by CCrVI*F, in which F is a pH-de-
pendent fraction determined by Eqs. (2)-(5) and depicted in Fig. 2B).
However, to achieve ﬁts to the available ex vivo reduction data, the pre-
dominance model of Schlosser and Sasso (2014) required optimizing
the model parameter, K11, resulting in a proposed K11 that is shifted
by more than two orders of magnitude (e.g., pK11 of 3.03 instead of
5.89) (Fig. 2B). Because the K11 corresponds to the Ka for chromate,
this results in lowering a parameter (Ka) that has been determined
with a reasonable degree of certainty from a value of 773,000 to 1,070,
which detracts from the chemistry-based approach, making it more of
an empirical model.
To date, a number of important limitations and gaps remain regard-
ing Cr(VI) reduction kinetics, including: (1) characterization of Cr(VI)
reduction using GF samples from fed individuals (i.e., previous data
were largely collected using samples from fasted individuals); (2) char-
acterization of Cr(VI) reduction at elevated pH (i.e., previous data sets
were very limited above pH of 4,which greatly hampered the character-
ization of the pH-dependence for Cr(VI) reduction); and (3) character-
ization of individual variation in fasted, fed, and PPI samples (i.e.,
previous data sets relied primarily upon pooled fasted GF samples).
The followingwork describes a series of experiments using samples ob-
tained from De Flora et al. (2016), and kinetic modeling designed to ad-
dress many of these data gaps and limitations, with the ultimate goal of
providing data to support pharmacokineticmodeling andhuman health
risk assessment for Cr(VI) (Fig. 1).
2. Material and Methods
2.1. Gastric Sample Collection and Analysis
GF samples were collected from three groups: (1) eight healthy
human volunteers in Italy (n=8, pH 1.7 to 3.5) who provided pre-
and post-meal samples (as described in De Flora et al., 2016); (2) one
volunteer who provided a post-meal (vomit) sample (pH 1.8); and
(3) three pre-operative patients on PPIs (GF pH5 to 7.5) at DukeUniver-
sity Hospital who provided fasted samples. For samples in the group 1,only 7/8 fed samples were analyzed, which when combined with the
group 2 sample yielded a total of 8 fed samples analyzed. Similarly,
only 5/8 fasted samples from group 1 were analyzed. Because the PPI
samples were collected from anonymous patients, the Duke University
IRB determined that IRB approval (Protocol ID Pro00028884) was not
required, and the study satisﬁed the Privacy Rule as described in 45
CFR 164:514. From the volunteers in Italy, nasogastric tubes were
used to collect the gastric samples: pre-meal (fasted) samples were col-
lected after an overnight fast and post-meal (fed) samples were collect-
ed 1.5 h after lunch. These samples were centrifuged at 1,000xg, and
gross food residues were removed (De Flora et al., 2016). Pre-operative
patients on PPIs at Duke University Hospital were fasted for aminimum
of 7 h before sample collection. Collection of the GF was performed as a
routine part of the standard pre-operative procedure, and was declared
by the Duke Institutional Review Board to be research not involving
human subjects. Sampleswere collected by laboratory personnel imme-
diately after removal from the patient’s stomach (just before thoracic
surgery, after anesthesia was induced). Samples were stored from 12
to 32 min at room temperature (allowing time to collect more than
one sample, to transport samples back to the laboratory, assess the pH
and aliquot the sample or samples) before the samples were ﬂash fro-
zen with liquid nitrogen. To assess the effect of sample collection and
handling on fed GF samples, a single vomit sample was collected from
an ill individual, without induction, approximately 3 h following a
meal. Use of this sample is exempt from IRB review in accordance
with 45 CFR 46:101(4). Using the available human gastric samples, sev-
eral ex vivo Cr(VI) reduction rate and capacity studieswere conducted at
Brooks Applied Labs (Bothell, WA) to evaluate the effect of GF dilution,
stomach condition (fed vs. fasted), and pH as well as inter-individual
variability in reduction and the presence of multiple reducing pools in
the human GF samples. Control samples were also used in each experi-
ment and consisted of 0.7% hydrochloric acid (HCl) in deionized (DI)
water.
All samples were analyzed for Cr(VI) and Cr(III) using Speciated Iso-
tope Dilution Mass Spectrometry (SIDMS) at Applied Speciation in
Bothell, WA in accordance with the methods described in Proctor et al.
(2012). Experimental design for each study is summarized in Table 1.
With the exception of Study 3, pH of the diluted sample was approxi-
mately the same as that of the undiluted sample (Table 1). The pH
and Eh of each gastric sample were measured before and after dilution.
Cr(VI) reductive capacity of each human gastric sample was mea-
sured ﬁrst, and then, the time-course studies of rate reduction were
conducted. Using ion chromatography Inductively Coupled Plasma
Mass Spectroscopy (IC-ICP-MS), Cr(VI) reductive capacity at 90 or 240
min in the human gastric samples [spiking concentrations of 0.1 to 10
mg/L Cr(VI)] were measured (Table 1). In this work we have extended
the time course to include time points longer than 60 min for several
reasons: (1) to provide amore accurate estimate of GF sample reduction
capacities; (2) to permit characterization of Cr(VI) reduction when
combinedwith very slow gastric transit times; and (3) to allow for char-
acterization of the reduction of Cr(VI) as lumen material transits
through the intestinal tract (e.g., small intestinal lumen).
After Cr(VI) reductive capacity was measured, SIDMS analyses were
conducted to quantify reduction rate at 0.25 to 240min (Table 1). As de-
scribed in Proctor et al. (2012), Cr(VI) (sodiumdichromate dihydrate or
SDD, primarily as the naturally abundant isotope 52Cr) was added to the
diluted gastric sample at concentrations ranging from 0.04 to 10.6 mg/L
Cr(VI) (Table 1). At each speciﬁed time point after spiking with SDD, a
1-10 μL sample was collected and enriched rare isotopes 53Cr(VI) and
50Cr(III) (Applied Isotope Technologies, Pittsburgh PA) were added.
Based on SIDMS, the concentration of Cr(VI) that remained in the gastric
sample from the SDD spike at each speciﬁc time point was determined.
For most of the time-course studies, a double-spike approach was
used to provide information on multiple reducing pools present in GF.
The ﬁrst Cr(VI) spikewas added at t≈ 0min to characterize rate and ca-
pacity at approximately 0.25, 5, and 20 min under low concentration
Table 1
Studies of Cr(VI) reduction capacity measured by IC-ICP-MS in gastric ﬂuids (GF) collected from human volunteers (fed and fasted) and pre-operative patients on PPIs (fasted).
Capacity Studies Time-Course Studies
Study
Number
Objective Sample Type1 Samples
ID
pH3 Dilution3 Volume
of Gastric
Fluid
Dilution3 Reaction
Time
Cr(VI) Spike
Concentrations
Volume
of Gastric
Fluid
Reaction
Time
Nominal Cr(VI)
Spike
Concentrations
4
1 Assess effect of
gastric ﬂuid dilution
Fed Human Pooled
(n=1)2
2, 4, 7,
12, 14,
16, 20
1.7 9:1 1 mL 9:1 90 10 mg/L 1 mL 0.5, 2, 5,
20, 60,
240 min
10 mg/L
2:1 2 mL 2:1 3 mL
2A Assess
inter-individual
variation in fed
samples
Fed Human
Individual (n=8)
14 2.0 9:1 0.5 mL 9:1 240 2.7 mg/L 0.3 mL 0.25, 5,
20, 90,
150 min
Initial =
0.1-1 mg/L
2.6-10.6 mg/L
at 30 min
16 2.5 0.5 mL 3.5 mg/L
2 2.0 0.5 mL 3.9 mg/L
4 3.5 0.5 mL 1.9 mg/L
7 2.0 0.3 mL 3.2 mg/L
20 2.0 0.5 mL 2.0 mg/L
12 2.0 0.5 mL 2.2 mg/L
2 5.8 0.5 mL 3.9 mg/L
22 1.8 0.5 mL 10 mg/L
2B Assess
inter-individual
variation in PPI
samples
PPI Human,
Individual (n=3)
P2 5 9:1 0.3 mL 9:1 240 0.1 mg/L 0.3 mL 0.25, 5,
20, 90,
150 min
Initial =
0.1 mg/L
1.0 mg/L
at 30 min
P19 6.0
P21 7.5 0.04 mg/L
2C Assess
inter-individual
variation in fasted
samples
Fasted Human,
Individual (n=5)
6 1.9 9:1 0.3 mL 9:1 240 3 mg/L 0.3 mL 0.25, 5,
20, 90,
150 min
Initial =
0.1 mg/L
2.6 mg/L
at 30 min
11 1.6 0.25, 5,
20, 90,
150 min
Initial =
0.1 mg/L
1.5 mg/L
at 30 min
15 2.5
17 1.6
19 1.6
3 Assess pH
dependence
Fed Human,
Individual (n=1,
evaluated at three
pH levels)
2 2.04,
4.7,
5.8
9:1 0.3 mL 9:1 240 0.1 mg/L 0.3 mL 0.5, 5, 20,
60, 120
min
0.04 mg/L
1 For each study, a control sample was used and consisted of 0.7% HCl and DI water. Fed and fasted GF samples were collected from 8 individuals; hence, 5 fasted human individuals in
Experiment 2C are actually a subset of 8 fed individuals.
2 In Study 1, two pooled samples of different dilutions (2:1 or 9:1) were tested. The pooled samples consisted of fed gastric ﬂuids from 7 volunteers as noted in the “Sample Used”
column.
3 For all experiments except Experiment 3, dilutions of gastric samples weremade using mixtures of HCl plus DI water to maintain the natural pH of undiluted gastric ﬂuid or content.
4 Sample at pH=2 reﬂects naïve, unadjusted sample from experiment 2A.
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= 30 min to characterize reduction kinetics at 90 and 150 min under
high concentration conditions (1-10 mg/L) (Table 1).2.2. Experimental Design
Using the analytical methods described above, a series of experi-
ments was conducted for the purposes of better characterizing the re-
duction of Cr(VI) by human GF samples (Table 1). Each experiment is
summarized brieﬂy below.2.2.1. Experiment 1: Effect of Dilution. As described previously (Proctor
et al., 2012), GF is a viscous ﬂuid that requires dilution to achieve a con-
sistency that allows for homogenization and analysis, and data collected
previouslywere done using a 9:1 dilution. To ensure that this dilution is
properly accounted for in the reduction model, time course data were
collected for up to 240 min to describe the reduction of Cr(VI) by a
pooled GF sample (fed) from seven individuals (GF collected within a
few hours post-meal). GF samples were diluted either 9:1 or 2:1 with
mixtures of DI water and HCl to maintain the natural pH of the pooled
sample (pH 1.7). The data collected from this experiment were then
modeled with a 3-pool pharmacokinetic model (see Pharmacokinetic
Modeling section below) with Cr(VI) concentration expressed one of
twoways: (1) in terms of the in vitro assay conditions (i.e., mg/L diluted
GF); and (2) in terms of GF volume (i.e., mg/L GF).2.2.2. Experiment 2: Characterization of Inter-Individual Variation. Time
course datawere collected for up to 240min to describe the reduction of
Cr(VI) by individual fed or fasted GF samples (Experiments 2A and 2C;
Table 1) and from fasted PPI users (Experiment 2B; Table 1). GF samples
were diluted 9:1 with DI water and HCl to maintain the natural pH of
the pooled sample. The data collected from this experiment were then
modeled in a step-wise manner using 1-, 2-, and 3-pool reduction
models. Pools were deﬁned as either ﬁrst [dependent only on Cr(VI)
concentration] or second order [dependent on Cr(VI) and reducing
agent concentration] reactions (see PharmacokineticModeling section).
To determine the number of pools required to provide the best overall
ﬁt, the modeling approaches were compared to assess model ﬁt to the
data using Akaike information criterion (AIC; see Pharmacokinetic
Modeling section).2.2.3. Experiment 3: Characterization of pH Dependence. Time course
data were collected for up to 240 min to describe the reduction of
Cr(VI) by GF samples from a single individual (GF collected approxi-
mately 1.5 h post-meal) at native pH (pH 2; sample 2 from experiment
2A; Table 1), and using the same sample with manually elevated pH
levels (pH 4.7 and 5.8). GF samples were diluted 9:1 with DI water
and HCl to achieve the desired pH levels. Values for the reduction rate
constants (see Pharmacokinetic modeling section) were estimated sep-
arately for each pH value, and restricting the initial RE concentration to
the same value in the model for all three simulations. To facilitate
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values were expressed as a fraction of the value obtained at native pH.
De Flora et al. (2016) assessed the amount of Cr(VI) reduced in 60
min by a single sample (native pH 2), with pH adjusted manually to
pH values of 2.5, 4, 5, 6, 7, and 8. Changes in the amount of Cr(VI) re-
duced in 60 min were assumed to be due to changes in the reduction
rate constants (i.e., reducing equivalents was assumed constant for all
pH values). Again, rate constant values were expressed as a fraction of
the value obtained at native pH.
Three published data sets for likely GF reducing agents (glutathione,
ascorbate, ferrous iron) were identiﬁed for characterizing the pH de-
pendence of Cr(VI) reduction across a range of pH value spanning at
least three pH units. These data sets include: (1) rate constants estimat-
ed from published time course data for Cr(VI) reduction by glutathione
(Wiegand et al., 1984); (2) published rate constants for Cr(VI) reduction
by ascorbate; and (3) published rate constants for Cr(VI) reduction by
ferrous iron (Buerge and Hug, 1997). Time-course data (up to 120
min) for Cr(VI) reduction by glutathione were generated at pH values
of 3, 4, 5, 6, 7, 7.4, and 8, and datawere obtained by digitizing theﬁgures
of Wiegand et al. (1984) using GraphClick (version 3.0.3). Rate con-
stants for each pH value were determined using a single-pool (i.e.,
only GSH present) reduction model. Rate constants for the reduction
of Cr(VI) by ascorbate were measured from pH values of approximately
3.5 to 8.8 for several different temperatures (17.85 – 35.1 degrees Celsi-
us; Dixon et al., 1993). Rate constant values collected at pH 8 and above
were excluded because they were not considered relevant for normal
gastric conditions. The behavior of the pH dependence was consistent
across all temperatures; however, the magnitude of the rate constants
was clearly temperature-dependent (higher rate constants at higher
temperatures). For this reason, the rate constant values were pooled
across temperatures by normalizing all values and expressing them as
a fraction of the maximum value estimated at pH 3.5 for each tempera-
ture. Rate constants for the reduction of Cr(VI) by ferrous iron were
measured from pH values of approximately 0.42 to 7.2 (Buerge and
Hug, 1997).
Data from Experiment 3 (Table 1) and fromDe Flora et al. (2016) for
GF weremodeled using a 3-pool reductionmodel, while published data
for single reductants were modeled using a 1-pool model. For all
models, it was assumed that pH dependence is due to effects on the
rate constant [or Cr(VI) predominance], and that the reducing agent
pools are independent of pH. For the 3-pool reduction model, it was
also assumed that the relationship between Cr(VI) reduction and pH is
the same for all three reducing agent pools (i.e., pH-dependent curves
for k1, k2, and k3 are parallel). These simplifying assumptionswere nec-
essary to obtain unique solutions and to ensure convergence during
model optimizations. Several pH-dependent relationships (log-linear,
piecewise log-linear, predominance) for the reduction rate constants
were evaluated, as described below.
2.3. Log-linear (Original Model)
Kirman et al. (2013) proposed a simple, log-linear model to describe
pH-dependence for a limited set of ex vivo reduction data:
Log kð Þ¼mpHþb ð6Þ
Where,
m = slope
b = intercept at pH 0
2.4. Piecewise Log-linear
As discussed by Kirman et al. (2013) the log-linearmodel may be an
oversimpliﬁcation in that “the pKa for chromate (5.9) might serve as an
inﬂection point for a nonlinear pH dependence of Cr(VI) reduction”. Forthis reason, a piecewise log-linear model was included in this evalua-
tion:
Log kð Þ ¼ m1  pH þ b1; if pHb ¼ P
Log kð Þ ¼ m2  pH þ b2; if pHNP ð7Þ
Where,
m1 = slope at low pH
b1 = intercept at low pH
m2 = slope at high pH
b2 = intercept at high pH
P = inﬂection point between low and high pH
Two forms of the piecewise log-linear model were considered: (1)
one in which the inﬂection point, P, is restricted to the published
value for pK11 of 5.89 (Brito et al., 1997); and (2) another in which P
was unrestricted, and optimized to ﬁt the available data sets.
2.5. Cr(VI) Predominance
As stated in the introduction, the form of Cr(VI) present in aqueous
media is pH dependent (Fig. 2A). Schlosser and Sasso (2014) proposed
to relate reduction of Cr(VI) to the form of Cr(VI) present at a given
pH. For comparing the behavior of this approach with the other ap-
proaches, their equations were adapted as follows:
k ¼ K  H2CrO4þHCrO4−þ f CrO42− =Þ Total Cr
  ð8Þ
Where,
K = rate constant (k1, k2, or k3) at pH 0
f = fraction of activity attributed to CrO42-
For the predominance model, the parameter K11 (Eq. (2)) deter-
mines the pH at which reduction reactivity decreases (analogous to pa-
rameter P in Eq. (7)). In this way, the rapid Cr(VI) reduction at low pH
(below pK11) is determined by the product, K*[H2CrO4+HCrO4-], while
slow reduction at high pH is determined by the product, K*f*[CrO42-]
(Fig. 2B). The pH dependence of this model is determined by the value
selected for pK11. Similar to the approach used by Schlosser and Sasso
(2014), two forms of the predominance model were included: (1) one
in which the pK11 is restricted to its published value of 5.89 (Brito et
al., 1997); and (2) another in which the pK11 term was unrestricted,
and optimized to ﬁt the available data sets.
2.6. Pharmacokinetic Modeling
2.6.1. Modeling to Evaluate the Number of Reducing Agent Pools. To
evaluate the number of reducing agent pools present in GF samples, a
total of six different forms reduction model were applied to the ex vivo
GF data. These reduction models differed with respect to the number
of reducing agent pools (n=1 to 3) and the order of the reaction (1st
or 2nd order):
1-Pool Models:
ReductionRate 1st orderreactionð Þ¼Cr VIð Þ k1ð Þ ð9Þ
ReductionRate 2nd orderreactionð Þ¼Cr VIð Þ k1RE1ð Þ ð10Þ
2-Pool Models:
ReductionRate one 1st and one 2nd orderreactionsð Þ¼Cr VIð Þ k1RE1þk2ð Þ
ð11Þ
ReductionRate two 2nd orderreactionsð Þ¼Cr VIð Þ k1RE1þk2RE2ð Þ ð12Þ
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ReductionRate one 1st and two 2nd orderreactionsð Þ
¼Cr VIð Þ k1RE1þk2RE2þk3ð Þ
ð13Þ
ReductionRate three 2nd orderreactionsð Þ
¼Cr VIð Þ k1RE1þk2RE2þk3RE3ð Þ
ð14Þ
Where,
Cr(VI) = concentration of hexavalent chromium (mg/L)
k1 = 1st or 2nd order rate constant (fast reaction)
k2 = 1st or 2nd order rate constant (slow reaction)
k3 = 1st or 2nd order rate constant (very slow reaction)
RE1 = concentration of reducing equivalents (mg/L, pool 1, fast)
RE2 = concentration of reducing equivalents (mg/L, pool 2, slow)
RE3= concentration of reducing equivalents (mg/L, pool 3, very slow)
The primary difference between the 1st and 2nd order reactions is
that the rate of the 2nd order reactions is decreased as capacity of the re-
ducing agents become depleted (i.e., RE concentration approaches
zero). Optimizations for the reduction models were performed by
adjusting the values for k (via the different pH-dependent equation pa-
rameters) and RE to maximize the model log-likelihood (LL) assuming
the error terms for the model are normally distributed.
LL ¼−n
2
ln 2πð Þ−n
2
lnσ2−
1
2σ2
Xn
i¼1
xi−μð Þ
2
: ð15Þ
Variance was assumed to be proportionate to the mean based on an
evaluation of duplicate sample data (CV=3%). Comparison of modelFig. 3. Assessment of reduction models ﬁt to human fed pooled sample at two different dilution
9:1 dilution modeled with concentration expressed in terms of per L diluted GF; (B) 9:1 dilu
normalized concentrations are 10x higher); (C) 2:1 dilution modeled with concentration expr
(same data as in panel C, but normalized concentrations are 3x higher). Diamonds = time-couperformance to the available data was assessed using AIC, calculated as:
AIC ¼ 2  n−2  LL ð16Þ
Where,
AIC = Akaike information criterion
n = number of estimated model parameters
LL = log likelihood function
For data sets in which optimal ﬁts were difﬁcult to obtain, the value
for the concentration of Cr(VI) at time zerowas allowed to vary by up to
20% to reﬂect uncertainty in starting conditions, consistent with the ap-
proach used by Schlosser and Sasso (2014).
2.6.2. Global Modeling. Data from all GF experiments (1-3), as well as
from previously published data sets for pooled fed human GF samples
(Kirman et al., 2013), yielding a total of 23 data sets, were modeled si-
multaneously using the number of reduction pools and pH dependence
as indicated by Experiments 1-3. After optimization, the capacity of each
reducing agent pool was characterized for fed and fasted individuals
(i.e., means and standard deviations). The global model was then ap-
plied to time course data for Cr(VI) reduction bymouse and rat GF sam-
ples from Proctor et al. (2012) (see Supplement 2), and reduction
capacities for each reduction pool were calculated. Three data sets
(one each for mouse, rat, and human GF) were withheld from global
model parameterization, and were used instead for the purpose of
model validation. Model predictions were compared graphically to
these data sets to assess themagnitude and behavior of the predictions.s to determine appropriate units for expressing Cr(VI) concentration (Experiment 1): (A)
tion modeled with concentration normalized to per L GF (same data as in panel A, but
essed in terms of per L diluted GF; (D) 2:1 dilution modeled with normalized to per L GF
rse data points as measured by SIDMS; Solid line = reduction model ﬁt to the data.
Table 2
Modeling Individual Data Sets: Evaluation of Reduction Model Complexity [Number of Cr(VI) Reducing Agent Pools] in Human GF Samples.
Reducing Agent Pools
Sample Group Number of Reducing
Agent Pools
Pool 1
(fast)
Pool 2
(slow)
Pool 3 (very
slow)
Maximum LL For All
Samples
Number of Estimated Parameters (each sample
optimized individually)
AIC
Experiment 2A (n=8 human
fed samples)
1 1st
order
NA NA -2452 8 4921
2nd
order
NA NA -782 16 1597
2 2nd
order
1st order NA -18 22 79
2nd
order
2nd
order
NA 6 30 48
3 2nd
order
2nd
order
1st order 88 32 -112
2nd
order
2nd
order
2nd order 88 40 -95
Experiment 2B (n=3 human
PPI samples)
1 1st
order
NA NA -159 3 325
2nd
order
NA NA 28 6 -44
2 2nd
order
1st order NA 53 9 -89
2nd
order
2nd
order
NA 75 12 -126.0
3 2nd
order
2nd
order
1st order 78 15 -126.3
2nd
order
2nd
order
2nd order 78 18 -120
Experiment 2C (n=5 human
fasted samples)
1 1st
order
NA NA -3659 5 7328
2nd
order
NA NA -54 10 127
2 2nd
order
1st order NA -51 15 133
2nd
order
2nd
order
NA 31 20 -22
3 2nd
order
2nd
order
1st order 42 25 -35
2nd
order
2nd
order
2nd order 33 30 -5
Bolded, italicized rows indicate the best ﬁtting reduction model with the lowest AIC for each sample group.
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3.1. Experiment 1: Effect of Dilution
Reductionmodel with rate constant expressed in terms of unadjust-
ed concentrations (e.g., on a diluted-GF basis) provided a betterﬁt to the
data than when concentrations were normalized to GF volume (AIC
values of 14.2 vs. 70.4; Fig. 3). These results are consistent with a chem-
ical reaction that is dependent upon the concentration of Cr in the reac-
tion vessel (e.g., mg Cr/L diluted GF), and thus, there is no need to
normalize concentrations to GF volume (e.g., mg Cr/L GF) as was done
for the previous version of the reduction model (Kirman et al., 2013).
Based upon these results, a diluted-GF basis was identiﬁed as the best
approach for the modeling work described below (Global Modeling
section).
3.2. Experiment 2: Identiﬁcation of the Number of Reducing Agent Pools
Reduction models with 1 to 3 reducing agent pools were applied to
time course data collected using GF samples from fed volunteers, fasted
volunteers, and PPI users. A comparison ofmodel AIC values is provided
in Table 2. For all three sample groups (fed, fasted, and PPI), the three-
pool model, with the ﬁrst two pools as 2nd order reactions, and third
pool as a 1st order reaction (i.e., Eq. (13)) provided the best overall ﬁt
to the data. Fits for the best-ﬁtting model are depicted in Fig. 4. Using
the dual spike approach, evidence of multiple pools is clearly evident
in these ﬁgures for samples in which the slope of time course data
after the low-concentration spike (time points 0-30 min) issubstantially steeper than the slope of the time course data after the
high-concentration spike (time points N30 min). A similar conclusion
was made for the presence of three pools in mouse and rat GF samples
(Supplement 2), consistent with the results of Schlosser and Sasso
(2014). Based upon these results, a three-pool model (Eq. (13)) was
identiﬁed as the best choice for the global modeling work described
below (Global Modeling section).
3.3. Experiment 3: Characterization of pH Dependence
Fits for a three-pool reduction model applied the data collected in
Experiment 3 data are depicted in Fig. 5A-C. Inspection of the k values
obtained from Experiment 3 does not suggest the presence of an inﬂec-
tion point between pH 2.0 and pH 5.8 (Fig. 5D). Because all three data
points from this experiment fall below a pH of 5.89 for chromate, the
piecewise log-linear 1 model cannot be used (reduces to the log-linear
model). The predominance 2 model (optimized pK11 = 3.11) provided
the best overall ﬁt to the data (Table 3; Fig. 5D). However, in order to ﬁt
the ex vivo data collected across pH levels, this model requires (1)
shifting the value for K11 by more than 2 orders of magnitude (opti-
mized pK11 of 3.11 vs. published value of 5.89); and (2) that the k values
obtained at pH 2 and 5.8 for Experiment 3 are at their respective maxi-
mum and minimum values, respectively (i.e., plateaus predicted at
pHb2 and pHN5.8). The log-linear model and piecewise log-linear
model 2 (optimized inﬂection point, P = 5.46) also perform reasonably
well with these data. The predominance model 1 (pK11 ﬁxed at 5.89)
provided a poor to ﬁt these data, largely because it predicts a constant
value (i.e., plateau) for the reduction constant below pH 5.
Fig. 4. Fits of a 3-pool reductionmodel applied to separately to example data sets from (A) a Fed GF Sample; (B) a PPI-User GF Sample; and (C) a Fasted GF Sample (ﬁts to all data sets are
provided in Supplement 1). Dark diamonds= time-course data points as measured by SIDMS for capacity runs(t=240min); Light diamonds= time-course data points as measured by
SIDMS (t=0-90 min); Solid lines = reduction model predictions.
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De Flora et al. (2016) are depicted in Fig. 6A. Inspection of the pH-de-
pendent behavior for k values obtained from these data does not sug-
gest the presence of a strong inﬂection point between pH 2.0 and pH
8.0. The piecewise log-linear model 2 (optimized P = 4.3) provided
the best overall ﬁt to the data (Table 3; Fig. 6A). The piecewise log-linear
model 1 (P ﬁxed at 5.89) also performs reasonably well with these data.
Both forms of the predominance model provided a poor ﬁt these data.
A comparison of the optimized pH-dependent model forms applied
to the glutathione rate constants obtained fromWiegand et al. (1984)
time course data is depicted in Fig. 6B. For these time course data, the
piecewise log-linear model 2 with pH (optimized P = 5.7) provided
the best overall ﬁt (Table 3). The optimized value for the inﬂection
point is fairly consistent (within half a pH unit) with the published
pK11 value of 5.89. The log-linear model performs poorly for this data
set, because it fails to capture the nonlinear behavior (i.e., inﬂection
point). Both forms of the predominance model perform poorly for
these data because their predicted behavior for reduction rate constant
(e.g., presence of plateaus) does not agree with the behavior needed to
ﬁt the time course data.
A comparison of the optimized pH dependent model forms applied
to the ascorbate rate constants reported by Dixon et al. (1993) is
depicted in Fig. 6C. For these data, the piecewise log-linearmodel 2 (op-
timized P=6.19) provided the best overall ﬁt (Table 3). In this case, the
optimized value for P is consistent (within half a pH unit) with the pub-
lished pKa value for chromate (5.89). Both forms of the predominance
model perform reasonablywell for this data set. However, the log-linear
model performspoorly because it fails to capture the nonlinear behavior
(i.e., apparent inﬂection point near pH 6).
A comparison of the optimized pH dependent model forms applied
to the reduction rate constants reported for ferrous iron by Buerge
and Hug (1997) is depicted in Fig. 6D. The pH-dependent behaviornoted for ferrous iron is clearly different than that observed for the
other data sets (i.e., apparent “U” shape). For these data, the piecewise
log-linear model 2 (optimized P = 4.3) provided the best overall ﬁt
(Table 3). The optimized value for the inﬂection point is considerably
lower than the published pKa value for chromate (5.89). Due to the un-
usual behavior of these data, all other models perform poorly.
Overall, the piecewise log-linear model 2 (with optimized inﬂection
point, P) provided the best ﬁt for 4 of 5 data sets, and nearly provided
bestﬁt for the remaining data set. For this reason, this formof the reduc-
tion model was identiﬁed as the best choice for modeling pH depen-
dence in the modeling work described below (Global Modeling
section).
3.4. Global Modeling
These results described above for Experiments 1, 2 and 3 were used
to guide the form of the global reduction model applied to all GF data
sets. Based upon these results, the data were modeled by expressing
Cr(VI) concentrations in terms of the diluted-GF basis (Experiment 1),
a three-pool reductionmodel was used (Experiment 2), and the pH-de-
pendence was deﬁned using a piecewise log-linear model 2 (Experi-
ment 3).
Optimized ﬁts of the global model to all data sets (Experiments 1, 2,
and 3, plus the data sets from Kirman et al., 2013) are provided in Sup-
plement 1. Based upon the combined ex vivo data set, the piecewise log-
linear model 2 yielded an optimized inﬂection point (P) of 5.3, with a
shallower slope indicated above this pH value (Fig. 7). The resulting for-
mulas for calculating pH-dependent reduction rate constants (k1, k2,
k3; Eq. (13)), as well as values for reducing equivalent concentrations
for each pool (RE1, RE2, RE3; Eq. (13)) are summarized in Table 4. The
predicted concentration of reducing equivalents in pool 1 (RE1) is great-
er in fasted samples than in fed samples (2.7 vs. 0.70 mg/L), while the
Fig. 5. Assessing the pH dependence for Cr(VI) reduction rate constants using data from Experiment 3: A) Three poolmodel ﬁt to data from Experiment 3A (native pH=2); B) Three pool
model ﬁt to data from Experiment 3A (adjusted pH =4.7); C) Three pool model ﬁt to data from Experiment 3A (adjusted pH =5.8); Dark diamonds = time-course data points as
measured by SIDMS for capacity runs(t=240 min); Light diamonds = time-course data points as measured by SIDMS (t=0-90 min); Solid lines = reduction model predictions; D)
Alternative pH-dependent model forms ﬁt to the data in panels 5A-C. X’s = rate constant values obtained from ﬁt time-course data in panes A-C; Lines = different pH-dependent
relationship predictions for the reduction rate constant.
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equivalents are generally higher in rats thanmice (Table 4; Supplement
2). Predictionsmade by the global reductionmodel for the three valida-
tion data sets (one for each species) are fairly consistentwith thebehav-
ior of the data (Fig. 8), with a slight tendency to overestimate the
amount of Cr(VI) left at the late time points, but in all cases the predict-
ed concentrations for Cr(VI) are within a factor of two of the measured
values.Table 3
Evaluation of pH-Dependent Model Forms for Cr(VI) Reduction.
AIC for Model Form
Data Set pH
Range
Reducing
Agent
Number
of Pools
Included
Log-linear Predominanc
1
(Inﬂection
point ﬁxed at
pH 5.88)
Time-Course Data for
Adjusted pH Sample
(Experiment 3)
2-5.8 Gastric
Fluid
3 -11 2,034
Time-Course Data for
Adjusted pH Sample
(De Flora et al., 2016)
2-8 Gastric
Fluid
3 33 480
Time-Course Data
(Wiegand et al., 1984)
3-8 Glutathione 1 15,978 17,247
Reduction Rate Constants
(Dixon et al., 1993)
3.53-7.9 Ascorbate 1 22,590 5,358
Reduction Rate Constants
(Buerge and Hug,
1997)
0.4 –
7.1
Iron(II) 1 18416 19068
Bolded, italicized values indicate the best ﬁtting model with the lowest AIC value.4. Discussion
A series of experimentswere conducted to support pharmacokinetic
modeling of Cr(VI) reduction. These data help address data gaps and
limitations with respect to (1) the expression of Cr(VI) concentrations
in the model; (2) the reduction of Cr(VI) in fed human GF samples;
(3) the number of Cr(VI) reduction pools present in human fed, fasted,
and PPI-user GF samples; and (4) an appropriate form for the pHe Predominance 2
(Inﬂection point
optimized, value in
parentheses)
Piecewise Log-linear 1
(Inﬂection point ﬁxed
at pH 5.89)
Piecewise Log-linear 2
(Inﬂection point optimized,
value in parentheses)
-25 (3.2) -11 (reduces to
log-linear model)
-23 (5.5)
55 (3.7) -19 -29 (4.3)
15,044 (5.0) 14,729 14,710 (5.7)
4,604 (5.8) 4,954 4,510 (6.1)
17311 (0.0) 13608 4671 (4.3)
Fig. 6. Assessing the pH dependence for Cr(VI) reduction rate constants using data from published data sets for GF (De Flora et al., 2016), glutathione (Wiegand et al., 1984), ascorbate
(Dixon et al., 1993), and Iron(II) (Buerge and Hug, 1997): A) Comparison of pH-dependent forms for reduction rate constant optimized to ﬁt GF data (De Flora et al., 2016); B)
Comparison of pH-dependent forms for reduction rate constant optimized to ﬁt glutathione time-course data (Wiegand et al., 1984); C) Comparison of pH-dependent forms for
reduction rate constant optimized to ﬁt published rate constants for ascorbate (Dixon et al., 1993); D) Comparison of pH-dependent forms for reduction rate constant optimized to ﬁt
published rate constants for iron(II) (Buerge and Hug, 1997); X’s = normalized rate constant values (relative to value at pH=2) used to ﬁt time-course data in panes A-C; Lines =
different pH-dependent relationship predictions for the reduction rate constant.
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herein provide improved characterization of Cr(VI) gastric reduction ki-
netics as compared to the original model in Kirman et al. (2013) and the
Schlosser and Sasso (2014) model.
In this study of human GF samples, we have speciﬁcally utilized a
dual spike approach to examine the presence of multiple reducing
agent pools in human GF samples under fed and fasted conditions, as
well as with PPI use. Together the available data are consistent with
the presence of three reducing agent pools being present in mouse,
rat, and human GF samples (i.e., there does not appear to be a species
difference with respect to the number of reducing agent pools present).
Use of a single pool model in previous work (Kirman et al., 2013;
Schlosser and Sasso, 2014) reﬂected a limitation of theprevious data set.Fig. 7. pH dependent Cr(VI) reduction rate constants based upon global optimization of a
three-pool, piecewise log-linear reduction model applied to all human time-course data
from Experiment 2A-C (optimized inﬂection point at pH = 5.3). Units for k1 and k2
(2nd order rate constants) are L2/mg-hr, and units for k3 (1st order rate constant) is L/hr.The reduction capacity of fed human samples, as estimated by sum-
ming the reducing equivalents concentrations for pools 1 and 2 (ap-
proximately 28 mg/L), is consistent with the data generated by De
Flora et al. (2016) using the DPC method in which reduction capacity
was 20.4± 2.61mg/L in post-meal samples. These results are also com-
parable to previous capacitymeasures by De Flora et al. (1987). Because
the precise time between meal consumption and GF sample collection
for the fed samples used in this study is not known, a better comparison
would be to compare the reduction capacity estimate of 28 mg/L to a
time-weighted average of the capacity measured up to a few h post
meal by De Flora et al. (1987), which is expected to fall somewhere be-
tween 10 mg/L and 60 mg/L. With respect to reduction capacity fasted
samples, the values derived here (approximately 16mg/L) is moderate-
ly higher than that reported by De Flora et al. (1987) (8.3 ± 4.7 mg/L)
and in De Flora et al. (2016) (10.3 ± 2.39 mg/L). These differences
may reﬂect in part, differences in incubation times used to assess
Cr(VI) reduction by GF (up to 240 min used here vs. 60 min used by
De Flora et al.).
An empirical model (piecewise log-linear model 2) was used to
characterize the pH-dependence of the reduction rate constants. This
model is slightly more complex than the log-linear model used previ-
ously (Kirman et al., 2013), in that additional model parameters were
introduced to permit an inﬂection point (P), as well as different slopes
above and below this pH value, but remains relatively simple to imple-
ment. Alternative pH-dependent models were also considered, includ-
ing the chemistry-motivated predominance model of Schlosser and
Sasso (2014), but these generally struggled to ﬁt somedata sets. The be-
haviors of the different pH-dependent forms assessed for the Cr(VI) re-
duction rate constants differ with respect to their inﬂection point, as
well as the presence or absence of plateaus. The plateau behavior pre-
dicted by the predominance models is driven by lumping of all forms
of Cr(VI), other than CrO4-2, together (Fig. 2). Based upon the data
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131C.R. Kirman et al. / Toxicology and Applied Pharmacology 306 (2016) 120–133evaluated for pH dependence (Experiment 3 of this study; De Flora et
al., 2016; Wiegand et al., 1984; Dixon et al., 1993; Buerge and Hug,
1997), there does not appear to be evidence to support the presence
of plateaus in the pH-dependence for reduction rate constants, as pre-
dicted by the predominance model of Schlosser and Sasso (2014).
When simultaneously ﬁt to all data sets, the piecewise log-linear
model 2 predicts a shallower slope (above the inﬂection point, than ob-
served below the inﬂection point (Fig. 7). This behavior differs from pH-
dependent behaviors observed for glutathione (Fig. 6B) and ascorbate
(Fig. 6C) assessed individually, where the slope observed at high pH is
steeper that that observed at low pH. One explanation for this apparent
difference in behavior may be the possible contribution of ferrous iron
at high pH. Ferrous iron exhibits an unusual (“U” shapes) behavior
with respect to Cr(VI) reduction (Fig. 6D). The study authors attributed
this behavior due to the predominance of different forms of iron present
at a given pH [e.g., Fe2+, FeOH+, Fe(OH)2], each ofwhichmayhave a dif-
ferent reaction rate with Cr(VI). Because dietary iron is predominantly
as the ferric form, the concentration of ferrous iron in the stomach
lumen is not expected to be high. Low concentrations of ferrous iron
are possible given the redox state of GF, such that predominance of
iron forms is in equilibrium with other reducing agents (sulfhydryls,
ascorbate) present in GF. In the small intestinal lumen, however, due
to the high activity of ferrous iron at high pH (Fig. 6D) and due to the re-
duction of ferric iron to ferrous iron (II) at the brush border of the small
intestine (required for iron absorption), ferrous iron may play a much
larger role in Cr(VI) reduction in the small intestinal lumen (Suh et al.,
2014).
The predominance models (1 and 2) assessed in this work are rela-
tively simple variations consistent with those proposed by Schlosser
and Sasso (2014), but could be extended to bemore complex. For exam-
ple, instead of combining redox active forms of Cr(VI) (H2CrO4 and
HCrO4-), different reduction activities could be attributed to each form
[e.g., k = K* (H2CrO4 + f1*HCrO4- + f2*CrO42-)/Total Cr]. In addition
to the predominance of Cr(VI) forms, the data of Buerge and Hug
(1997) indicate that the rate of reduction can also dependupon the pre-
dominance of the reducing agent forms [e.g., Fe2+, FeOH+, Fe(OH)2].
The plateau behavior predicted by the predominance model could be
eliminated by including a slope in place of the rate constant at pH 0
[e.g., k = (m*pH+b)* (H2CrO4 + f1*HCrO4- + f2*CrO42-)/Total Cr].
Such a model would be consistent with reduction models that include
a role for hydrogen ion in some reduction reactions (Connett and
Wetterhahn, 1983), but againwould require increasingmodel complex-
ity. It is not clear that such a complex model would provide a meaning-
ful beneﬁt over the comparatively simpler empirical model
recommended here (piecewise log-linear model).
Sasso and Schlosser (2015) recently assessed the impact of alterna-
tive reduction models on resulting internal dose measures as predicted
by a physiologically based pharmacokinetic model for Cr(VI) to support
human health risk assessment. Despite usingmodels that differ with re-
spect to complexity (single pool vs. three pools) and pH dependence
(e.g., log-linear vs. predominance 2 models), the authors reported
very similar results (i.e., within a factor of 2) for the points of departure
calculated for effects in themouse small intestine as compared to those
calculated by Thompson et al. (2014). In short, despite differences in
model complexity, alternative models yield quite similar reduction
rates. This is possible because the secondorder reduction rates are depen-
dent on three terms [i.e., Cr(VI)*k*RE]. In thisway, amodel that predicts a
low value for k can be consistent with a competing model that predicts a
higher value for k at a given pH, provided that reciprocal changes are
made for the RE terms (i.e., such that their products are the same). For
this reason, the selection of the form of the pH dependence for k can
have an indirect effect on the predicted values for reduction capacity.
The data and modeling presented here will be invaluable with re-
spect to supporting pharmacokinetic modeling and human health risk
assessment for Cr(VI). In particular, these data will be useful in charac-
terizing: (1) internal doses in humans exposed to Cr(VI) during a meal;
Fig. 8. Validation of the ﬁnal reduction model (three-pool, piecewise log-linear model) using three data sets: A) Pooled fed human GF sample; B) Mouse GF sample; C) Rat GF sample.
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and fasted states; and (3) inter-individual variation in a potentially sen-
sitive subpopulation (e.g., neonates, PPI users). The presence ofmultiple
pools in human GF, in particular, has important implications to low-
dose risk predictions. Speciﬁcally, the presence of a fast but low capacity
reduction reaction (RE pool 1; Eq. (13)) predicts a more efﬁcient detox-
iﬁcation of Cr(VI) at low concentrations (e.g., below the capacity of pool
1), than at higher concentrations in which detoxiﬁcation becomes de-
pendent upon slower detoxiﬁcation reaction rates (RE pools 2 and 3).
The capacity of the pool 1 for fed conditions, which is lower than that
for fasted conditions, is 0.7 mg/L, which far exceeds typical human
drinking water exposure to Cr(VI) considering the federal maximum
contaminant level is 0.1 mg/L, and recent drinking water exposure
data for Cr(VI) collected by the US Environmental Protection Agency
(USEPA) indicate that mean levels of Cr(VI) in drinking water across
theUS are less than 0.001mg/L (USEPA, 1991, 2016). As such, at expect-
ed drinking water exposures, detoxiﬁcation of Cr(VI) by reduction to
Cr(III) should be rapid (less than 1 minute). Therefore, extrapolation
of the cancer incidence observed in rodents exposed to very high con-
centrations of Cr(VI) to human populations exposed to low concentra-
tions of Cr(VI) will need to quantify the dose-dependent, nonlinear
toxicokinetics (i.e., sequential depletion of RE pools 1 and 2) in order
to provide an accurate depiction of low-dose risks fromCr(VI) exposure,
and will need to be able to quantify risk in sensitive subpopulations
(e.g., neonates, PPI users).
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